CD47 Antigen Inhibitors Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight
The rising global cancer incidence is a key factor driving the CD47 inhibitors market, as the demand for novel therapies grows. Recent clinical trials have demonstrated promising results, particularly in hard-to-treat cancers like AML, boosting investor confidence. A strong pipeline of investigational drugs candidates like evorpacept, PT217 is expected to accelerate market expansion. Additionally, increased R&D investments and strategic collaborations highlight the industry’s commitment to advancing CD47-targeted immunotherapies.
New York, USA, Feb. 24, 2025 (GLOBE NEWSWIRE) — CD47 Antigen Inhibitors Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight
The rising global cancer incidence is a key factor driving the CD47 inhibitors market, as the demand for novel therapies grows. Recent clinical trials have demonstrated promising results, particularly in hard-to-treat cancers like AML, boosting investor confidence. A strong pipeline of investigational drugs candidates like evorpacept, PT217 is expected to accelerate market expansion. Additionally, increased R&D investments and strategic collaborations highlight the industry’s commitment to advancing CD47-targeted immunotherapies.
DelveInsight’s ‘CD47 Antigen Inhibitors Pipeline Insight 2025‘ report provides comprehensive global coverage of pipeline CD47 antigen inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CD47 antigen inhibitors pipeline domain.
Key Takeaways from the CD47 Antigen Inhibitors Pipeline Report
- DelveInsight’s CD47 antigen inhibitors pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline CD47 antigen inhibitors.
- Key CD47 antigen inhibitor companies such as ImmuneOncia Therapeutics, Molecular Partners AG, HanchorBio, Phanes Therapeutics, Hanxbio, Pfizer, Innovent Biologics, Alexo Therapeutics, Hutchmed, and others are evaluating new CD47 antigen inhibitors drugs to improve the treatment landscape.
- Promising pipeline CD47 antigen inhibitors such as IMC-002, MP 0621, HCB-101, PT-217, HX 009, Maplirpacept, IBI 322, ALX-148, HMPL-A83 and others are under different phases of CD47 antigen inhibitors clinical trials.
- In January 2025, ALX Oncology Holdings announced positive updated data from the ASPEN-06 Phase II clinical trial demonstrating that the company’s investigational CD47-blocker evorpacept generates a durable clinical response with a well-tolerated safety profile among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.
- In December 2024, The US FDA had granted fast track designation to PT217 for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer.
- In December 2024, Molecular Partners announced the presentation of additional data pertaining to two programs, including preclinical data on MP0621, a potential next-generation conditioning regimen for patients undergoing hematopoietic stem cell transplantation, and comprehensive data from the first seven cohorts of the ongoing phase I/IIa dose-escalation study of MP0533.
- In August 2024, Phanes Therapeutics announced that the US Food and Drug Administration (FDA) had granted orphan drug designation (ODD) to PT217 for the treatment of neuroendocrine carcinoma (NEC).
- In June 2024, Immuneoncia announced the results of its solid tumour Phase Ia clinical trial of IMC-002, an anti-CD47 mAb, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Request a sample and discover the recent advances in CD47 antigen inhibitors drugs @ CD47 Antigen Inhibitors Pipeline Report
CD47 Antigen Inhibitors Overview
CD47, often referred to as the “don’t eat me” signal, is a transmembrane protein that plays a pivotal role in immune evasion by cancer cells. It binds to signal regulatory protein alpha (SIRPα) on macrophages, transmitting an inhibitory signal that prevents phagocytosis. This mechanism allows cancer cells to escape immune surveillance, contributing to tumor progression and metastasis. CD47 antigen inhibitors are an emerging class of immunotherapeutic agents designed to block the interaction between CD47 and SIRPα, thereby reactivating macrophage-mediated phagocytosis. By enhancing the immune system’s ability to target and destroy tumor cells, these inhibitors represent a promising approach for treating various malignancies, including hematologic cancers and solid tumors.
Several CD47 antigen inhibitors, including monoclonal antibodies and fusion proteins, are currently undergoing clinical trials. These agents are being tested as monotherapies and in combination with other treatments, such as immune checkpoint inhibitors or chemotherapy, to amplify anti-tumor responses. Early results have demonstrated encouraging efficacy, with manageable safety profiles, although challenges like potential off-target effects on healthy cells expressing CD47 remain a concern. The therapeutic potential of CD47 inhibitors extends beyond oncology, with research exploring their utility in autoimmune disorders and transplantation. As a frontier in immunotherapy, CD47 inhibitors exemplify the shift toward harnessing innate immunity to complement existing adaptive immune-targeting strategies.
Find out more about CD47 antigen inhibitor drugs @ CD47 Antigen Inhibitors Analysis
A snapshot of the Pipeline CD47 Antigen Inhibitors Drugs mentioned in the report:
| Drugs | Company | Phase | Indication | RoA |
| ALX148 | ALX Oncology | Phase II/III | Gastric Cancer | Intravenous |
| Maplirpacept | Pfizer | Phase II | Hematological Malignancies | Intravenous |
| Ligufalimab | Akeso Biopharma | Phase II | Advanced Hepatocellular Carcinoma | Intravenous |
| HCB101 | HanchorBio | Phase I/II | Solid Cancer | Intravenous |
| PT217 | Phanes Therapeutics | Phase I/II | Small Cell Lung Cancer | Intravenous |
Learn more about the emerging CD47 antigen inhibitors @ CD47 Antigen Inhibitors Clinical Trials
CD47 Antigen Inhibitors Therapeutics Assessment
The CD47 antigen inhibitors pipeline report proffers an integral view of the emerging CD47 Antigen inhibitors segmented by stage, product type, molecule type, and route of administration.
Scope of the CD47 Antigen Inhibitors Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Intravaginal, Oral, Parenteral, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Vaccines, Monoclonal antibody, Peptides, Polymer, Small molecule
- Key CD47 Antigen Inhibitors Companies: ImmuneOncia Therapeutics, Molecular Partners AG, HanchorBio, Phanes Therapeutics, Hanxbio, Pfizer, Innovent Biologics, Alexo Therapeutics, Hutchmed, and others
- Key CD47 Antigen Inhibitors Pipeline Therapies: IMC-002, MP 0621, HCB-101, PT-217, HX 009, Maplirpacept, IBI 322, ALX-148, HMPL-A83, and others
Dive deep into rich insights for new CD47 antigen inhibitors, visit @ CD47 Antigen Inhibitors Drugs
Table of Contents
| 1. | CD47 Antigen Inhibitors Pipeline Report Introduction |
| 2. | CD47 Antigen Inhibitors Pipeline Report Executive Summary |
| 3. | CD47 Antigen Inhibitors Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | CD47 Antigen Inhibitors Clinical Trial Therapeutics |
| 6. | CD47 Antigen Inhibitors Pipeline: Late-Stage Products (Pre-registration) |
| 7. | CD47 Antigen Inhibitors Pipeline: Late-Stage Products (Phase III) |
| 8. | CD47 Antigen Inhibitors Pipeline: Mid-Stage Products (Phase II) |
| 9. | CD47 Antigen Inhibitors Pipeline: Early-Stage Products (Phase I) |
| 10. | CD47 Antigen Inhibitors Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the CD47 Antigen Inhibitors Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the CD47 Antigen Inhibitors Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the CD47 antigen inhibitors pipeline therapeutics, reach out @ CD47 Antigen Inhibitors Therapeutics
Related Reports
CD47 Antigen Inhibitors Market
CD47 Antigen Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CD47 antigen inhibitors companies, including ALX Oncology, Phanes Therapeutics, Pfizer, Akeso Biopharma, ImmuneOnco Biopharma, among others.
Small Cell Lung Cancer Market
Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.
Small-cell Lung Cancer Pipeline
Small-cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small-cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, among others.
Non-Small Cell Lung Cancer Market
Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key NSCLC companies including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, among others.
Non-small Cell Lung Cancer Pipeline
Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NSCLC companies, including Merck Sharp & Dohme LLC, AbbVie, Qilu Pharmaceutical Co., Ltd., Suzhou Puhe Pharmaceutical Technology Co., LTD, Exelixis, Genmab, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Immunitas Therapeutics, Hansoh BioMedical R&D Company, Mythic Therapeutics, Shanghai Henlius Biotech, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.